Issue 5, 2022

Synthesis and structure–activity relationships of pirfenidone derivatives as anti-fibrosis agents in vitro

Abstract

Pirfenidone (PFD) was the first approved drug by FDA for the treatment of idiopathic pulmonary fibrosis (IPF). However, the rapid metabolism of 5-methyl of PFD increases the risk of side effects in clinics. Thus, in this paper, a common practice that a stable amide bond linking various groups used to replace 5-methyl of PFD in medicinal chemistry was applied, and total 18 PFD derivatives were synthesized. All compounds were investigated for their antiproliferation activities against NIH3T3 cells and the structure–activity relationships of the target compounds were also discussed. Among them, YZQ17 possessed potent antiproliferation activity compared to PFD and better potency in inhibiting TGF-β-induced migration of NIH3T3 cells at a much lower concentration than that of PFD. In addition, YZQ17 dramatically inhibited the expression levels of fibrotic markers α-SMA, collagen I, and fibronectin. Moreover, further mechanistic studies confirmed that YZQ17 exhibited this considerable anti-fibrosis activity via the TGF-β/Smad2/3 dependent pathway. Finally, the results of human and rat liver microsomes assay in vitro and pharmacokinetic assay in rats confirmed that YZQ17 showed better pharmacokinetics than that of PFD. Collectively, the preliminary study of PFD derivatives modified by the amide group indicated that YZQ17 could be regarded as a lead compound for further investigation and optimization.

Graphical abstract: Synthesis and structure–activity relationships of pirfenidone derivatives as anti-fibrosis agents in vitro

Supplementary files

Article information

Article type
Research Article
Submitted
31 Dec 2021
Accepted
28 Mar 2022
First published
01 Apr 2022

RSC Med. Chem., 2022,13, 610-621

Synthesis and structure–activity relationships of pirfenidone derivatives as anti-fibrosis agents in vitro

X. Shi, Z. Yu, C. Zhu, L. Jiang, N. Geng, X. Fan, Z. Guan and X. Lu, RSC Med. Chem., 2022, 13, 610 DOI: 10.1039/D1MD00403D

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements